– Plans for filing an IND was agreed with the FDA in a recent meeting –

Six-month primate HAV CABG model demonstrates patency, recellularization and remodeling resembling native blood vessels HAV may address many limitations of current standard of care grafts used in CABG procedure DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue […]

— Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease– — Small-diameter HAV observed to maintain patency and exhibit host-cell remodeling at six months post-implantation in a non-human primate model– –Results presented at American Heart Association Basic Cardiovascular Sciences Scientific Sessions 2022 — DURHAM, N.C., July 25, […]

— Patency and host cell remodeling of the HAV were observed in all study implants – — Preclinical study is one component of Humacyte’s expansion of the testing of the HAV in a broader cardiac bypass surgery application – DURHAM, N.C., Nov. 16, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing […]